Medical device maker Boston Scientific Corporation (NYSE: BSX) reported financial results for the second quarter of 2023. The company also provided guidance for fiscal 2023.
- The company reported net sales of $3.599 billion for Q2, representing an 11% year-over-year increase, and an 11.6% growth on an organic basis
- Net income attributable to stockholders, on an unadjusted basis, was $261 million, compared to $246 million in the year-ago period
- Net income per share came in at $0.18 per share, slightly higher than the $0.17 per share reported last year
- Second-quarter adjusted earnings increased to $0.53 per share from $0.44 per share in the same period of last year
- The management expects net sales to grow in the range of 10.5% to 11.5% in fiscal 2023 on a reported basis, and 10-11% on an organic basis
- Full-year net income, including special items, is expected to be between $0.87 per share and $0.93 per share; the forecast for adjusted EPS is $1.96-$2.00
Most Popular
Key highlights from Carnival Corporation’s (CCL) Q3 2023 earnings results
Carnival Corporation & plc (NYSE: CCL) reported third quarter 2023 earnings results today. Revenues were $6.9 billion compared to $4.3 billion in the same period last year. On a GAAP basis,
NKE Earnings: Here’s everything you need to know about Nike’s Q1 report
Nike, Inc. (NYSE: NKE) on Thursday reported results for the first three months of fiscal 2024, reporting a modest rise in revenues. The sneaker giant reported net income of $1.45
Key takeaways from Accenture’s (ACN) Q4 2023 earnings report
Shares of Accenture plc (NYSE: ACN) were down 4% on Thursday after the company delivered mixed results for the fourth quarter of 2023 and provided full-year guidance that came below
